Corporate influence over clinical research: Considering the alternatives

Prescrire International

Volumn 21, Issue 129, 2012, Pages 191-194

  Gagnon, Marc André ^a,b  

^a CARLETON UNIVERSITY   (Canada)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; NEUROLEPTIC AGENT; PAROXETINE; ROFECOXIB; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL RESEARCH; CRISIS THEORY; DRUG INDUSTRY; DRUG MARKETING; FUNDING; HEALTH CARE COST; HUMAN; ORGANIZATION AND MANAGEMENT; PHARMACEUTICAL CARE; PRESCRIPTION; PUBLICATION; REVIEW;

BIOMEDICAL RESEARCH; DRUG INDUSTRY; HUMANS; PUBLIC SECTOR; PUBLISHING; RESEARCH SUPPORT AS TOPIC;

EID: 84864571099     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Gagnon MA and Lexchin J "The Cost of Pushing Pills" PLoS Medicine 2008; 5 (1).
2. Prescrire Editorial Staff "A look back at 2009: one step forward, two steps back" Prescrire Int 2010; 19 (106): 89-94.
3. Conseil d'examen du prix des médicaments brevetés (CEPMB) "Rapport annuel 2010" Ottawa: 2011.
4. Mamou Y "La pharmacie en quête d'une recherche plus efficace" Le Monde, 3 janvier 2008.
5. Gagnon MA "The Nature of Capital in the Knowledge-Based Economy: The Case of the Global Pharmaceutical Industry" PhD Dissertation in Political Science, York University, Canada, 2009.
6. Girgis RR et al. "Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial" British Journal of Psychiatry 2011; (199): 281-288.
7. Matheson A "Corporate Science and the Husbandry of Scientific and Medical Know ledge by the Pharmaceutical Industry". BioSocieties 2008; 3:355-382.
8. Sismondo S "Ghosts in the Machine: Publication Planning in the Medical Sciences" Social Studies of Science 2009; (39): 171-198.
9. Sismondo S "Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry?" PLoS Medicine 2007; 4 (9).
10. Fugh-Berman A "The Haunting of Medical Journals: How Ghostwriting Sold "HRT"" PLoS Medicine 2010; 7 (9).
11. Ross JS et al. "Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation" JAMA 2008; 299 (15).
12. Edwards J ""CASSPER" was GSK's Friendly Ghostwriting Program on Paxil" BNET 20 August 2009.
13. Turner EH et al. "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy" New England Journal of Medicine 2008; 358 (3): 252-260.
14. Fournier JC et al. "Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis" JAMA 2010; 303 (1): 47-53.
15. Frachon I "Retrait du benfluorex (Mediator°): le praticien, la pharmacovigilance et les autorités de santé" Presentation delivered at Prescrire's 2011 Pilule d'Or ("Golden Pill") ceremony; 27 January 2011: 3 pages.
16. Rout M "Vioxx maker Merck and Co drew up doctor hit list" The Australian 1 April 2009.
17. U.S. Senate Committee of Finance "Grassley, Baucus Release Committee Report on Avandia" Press release, 20 February 2010.
18. Stevens AJ "The Role of Public-Sector Research in the Discovery of Drugs and Vaccines" NEJM; 2011; 364 (6).
19. Sampat BN and Lichtenberg F "What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?" Health Affairs 2011; 30 (2).
20. Light D "Basic research funds to discover important new drugs: who contributes how much?" in "Monitoring Financial Flows for Health Research 2005; Behind the Global Numbers", edited by Global Forum for Health Research. Geneva: Global Forum for Health Research, 2006.
21. OCDE "Science, technologie et industrie : Tableau de bord de l'OCDE 2011 - L'innovation et la croissance dans les économies du savoir" OCDE 2011.
22. See for example Gagnon MA "The Economic Case for Universal Pharmacare" Canadian Centre for Policy Alternatives 2010.
23. Congressional Budget Office "Reducing the Deficit; Spending and Revenue Options". March 2011.